Autologous Biologic Therapies for Osteoarthritis Management

Autologous biologic therapies harness a patient’s own blood or marrow components to modulate inflammation and support tissue repair in osteoarthritis. These interventions include platelet-rich plasma (PRP), autologous conditioned serum (ACS) and autologous protein solution (APS). By concentrating growth factors, anti-inflammatory cytokines and cellular elements, they aim to reduce joint pain, improve function and slow cartilage degeneration in early to moderate stages of knee and hip osteoarthritis. Preparation methods differ in centrifugation parameters, incubation times and device design, yielding products with distinct cytokine and cell profiles that determine therapeutic potency and duration of effect.

Mechanistic studies indicate that PRP delivers platelet-derived growth factors which stimulate chondrocyte proliferation and matrix synthesis, while ACS and APS focus on elevating interleukin-1 receptor antagonist (IL-1Ra) to counteract pro-inflammatory cytokines. The balance between anabolic and inflammatory mediators within each preparation governs its net disease-modifying potential. Emerging developments also explore the role of white blood cells and progenitor cells in refining the anti-catabolic and immunomodulatory properties of these autologous therapies. Standardisation of processing protocols and identification of patient-specific predictors of response remain critical to achieving consistent clinical outcomes.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Autologous Biologic Therapies for Osteoarthritis Management publication trend

The graph below shows the total number of articles in autologous biologic therapies for osteoarthritis management across all publications each year (not limited to Nature Index journals).

Technical terms

Platelet-rich plasma (PRP): A concentrated suspension of autologous platelets in plasma, rich in growth factors that promote tissue regeneration.

Autologous conditioned serum (ACS): Patient-derived serum incubated to enhance anti-inflammatory cytokines, notably interleukin-1 receptor antagonist, for intra-articular use.

Autologous protein solution (APS): A blood-based concentrate combining platelets and white blood cells designed to elevate anti-inflammatory cytokines and anabolic factors.

Interleukin-1 receptor antagonist (IL-1Ra): An endogenous inhibitor of interleukin-1 signalling that mitigates joint inflammation and cartilage catabolism in osteoarthritis.

References

1. Comparisons of Cytokines, Growth Factors and Clinical Efficacy between Platelet-Rich Plasma and Autologous Conditioned Serum for Knee Osteoarthritis Management. Biomolecules (2023).
2. Individual immune cell and cytokine profiles determine platelet-rich plasma composition. Arthritis Research & Therapy (2023).
3. White blood cell concentration correlates with increased concentrations of IL‐1ra and improvement in WOMAC pain scores in an open‐label safety study of autologous protein solution. Journal of Experimental Orthopaedics (2016).